Reflux Clinical Trial
— ES-REFLUJOOfficial title:
Protocol for the ESREFLUJO Study: Epidemiological Study of Heartburn and Gastroesophageal Reflux in Community Pharmacy
Verified date | December 2021 |
Source | Universidad Miguel Hernandez de Elche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Introduction: Symptoms as heartburn and/or reflux is frequent consultations in community pharmacies, the characterization of them is crucial to provide appropriate patient counseling. To facilitate the assistance work of the community pharmacist and its coordination between different levels of care, a group of experts in Community Pharmacy, Primary Care, and Gastroenterology has recently worked on an algorithm to manage these symptoms. Objective: Analyse the epidemiological characteristics of patients who consult for symptoms of heartburn and/or reflux in Spanish community pharmacies, and evaluate the clinical and humanistic results of the protocolization of a Professional Pharmaceutical Service in said patients. Methods and analysis: The study design consists of a cross-sectional descriptive part, in which the clinical and sociodemographic characteristics of the patients who come to the community pharmacy will be evaluated for consultation derived from heartburn and/or reflux symptoms and a before-after descriptive study in which will evaluate the clinical and humanistic results in patients who come to the pharmacy after receiving pharmaceutical care.
Status | Not yet recruiting |
Enrollment | 1200 |
Est. completion date | September 1, 2022 |
Est. primary completion date | July 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Population´s age = 18 years - Patients who consult for mild symptoms of heartburn and/or gastroesophageal reflux or request treatment for it. Exclusion Criteria: - Subjects who request treatment for symptoms of heartburn and/or gastroesophageal reflux for another person - Women with high-risk pregnancies |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Universidad Miguel Hernandez de Elche |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Collection of sociodemographic data of participants | At the initial visit, sociodemographic variables will be collected through a Data Collection Notebook (CDR): sex, age, level of education, employment status, civil status. | 8 minutes each questionnaire | |
Primary | Collection of clinical data of participants | At the initial visit, clinical data will be collected through a Data Collection Notebook (CDR):
Risk factors: Body mass index (BMI), smoking, food consumption • Weight and height will be combined to report BMI in kg/m^2. Symptoms throught the questionnaire: The Gastro-oesophageal Reflux Disease Impact Scale (GIS) Treatments or medications used |
8 minutes each questionnaire | |
Primary | Detail the evolution of the patient's symptoms 14 days after intervention | An independent external monitor will make a telephone call to each patient to collect the evolution of the patient´s symptoms through a questionnaire: The Gastro-oesophageal Reflux Disease Impact Scale (GIS). It is a scale of frequency, the lower scores mean better health in the patient less frequency of disturbances) | 5 minutes | |
Primary | Evaluate patient satisfaction | An independent external monitor will make a telephone call to each patient to collect the evolution of the patient´s symptoms through a questionnaire: Degree of satisfaction with the pharmaceutical care received (The score is the level of agreement, high punctuation means more satisfaction) and If the patient gets medication: Treatment Satisfaction Questionnaire for Medication (TSMQ, v1.4). (The score is the level of satisfaction, high punctuation means more satisfaction) | 5 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01406210 -
RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol
|
N/A | |
Completed |
NCT01263626 -
Cough Monitoring Study
|
N/A | |
Completed |
NCT01154634 -
Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects
|
Phase 2 | |
Recruiting |
NCT05629143 -
Primary carE PPi dEprescRibing Trial
|
Phase 4 | |
Recruiting |
NCT05899491 -
Role of ARMA in Selective Subset of Refractory GERD Patients.
|
N/A | |
Active, not recruiting |
NCT02001727 -
HEP-FYN 12-Years Follow-up
|
N/A | |
Completed |
NCT00863161 -
Renal Impairment Study
|
Phase 1 | |
Active, not recruiting |
NCT00161096 -
On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication
|
Phase 3 | |
Completed |
NCT00519441 -
Do Patients Who Have Had Surgery for Achalasia Suffer From Reflux
|
N/A | |
Completed |
NCT00175045 -
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
|
Phase 2 | |
Terminated |
NCT04006002 -
Mechanism of Weight Loss After Endoscopic and Laparoscopic Sleeve Procedures
|
||
Completed |
NCT02048449 -
Inter-rater Reliability of the Reflux Finding Score Among Gastroenterologists
|
N/A | |
Completed |
NCT00842387 -
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
|
N/A | |
Unknown status |
NCT00216788 -
The Effect of Nexium on Transmucosal Esophageal Leak
|
Phase 1 | |
Completed |
NCT01509352 -
Prospective Randomized Trial Evaluating the Utility of Esophageal Stitches During Laparoscopic Fundoplication
|
N/A | |
Completed |
NCT04329000 -
On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.
|
N/A | |
Enrolling by invitation |
NCT05041608 -
Endoscopic Surgery for Gastrointestinal Disorders: A Multicenter Registry Study
|
||
Completed |
NCT02226484 -
Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
|
Phase 1 | |
Completed |
NCT00687245 -
Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)
|
Phase 1 | |
Recruiting |
NCT03418350 -
The Role of Laryngopharyngeal Reflux in IPF
|